Home
About
Pricing
Log In
Back
EMDAAC

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

10
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Emyria Limited - Option Expiring 22-Mar-2027 Deferred

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

empty share chartempty share line

Performance graph isn't available yet for this share

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in EMDAAC

10

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in EMDAAC

N/A
EMDAAC investor breakdown
πŸ’΅ Income of investors

More than 200k

15%

150k - 200k

8%

100k - 150k

15%

50k - 100k

23%

Less than 50k

38%
πŸ‘Ά Age of investors

18 - 25

26 - 34

20%

35 - 90

70%
πŸ™‹ Legal gender of investors

Female

70%

Male

30%

Pearlers who invest in EMDAAC also invest in...

Emyria Limited

EMD

Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

πŸ™Œ Performance (5Yr p.a)

-8.24%

πŸ“Š Share price

$0.05 AUD

πŸ“¦ LOGISTICS

Find Out More

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

πŸ™Œ Performance (5Yr p.a)

10.28%

πŸ“Š Share price

$36.03 AUD

🌏 GLOBAL

πŸ’Έ FINANCIALS

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax

πŸ™Œ Performance (5Yr p.a)

10.70%

πŸ“Š Share price

$107.91 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 877 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australia’s resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.

πŸ™Œ Performance (5Yr p.a)

108.81%

πŸ“Š Share price

$2.31 AUD

πŸ•ŠοΈ SOCIALLY AWARE

⛏️ MINING

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

9.31%

πŸ“Š Share price

$109.85 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

🧱 MATERIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

πŸ’Έ FINANCIALS

Want more shares? Try these...

Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

πŸ™Œ Performance (5Yr p.a)

-8.24%

πŸ“Š Share price

$0.05 AUD

πŸ“¦ LOGISTICS